Results 141 to 150 of about 4,762 (170)
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. [PDF]
Mol Cancer Ther, 2014 Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, Qi J, Stone RM, Wadleigh M, Bradner JE, Frank DA. +10 moreeuropepmc +1 more sourceThe transcriptional modulator BCL6 as a molecular target for breast cancer therapy. [PDF]
Oncogene, 2015 Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA. +9 moreeuropepmc +1 more sourceThe kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. [PDF]
Blood Adv, 2018 Liu S, Marneth AE, Alexe G, Walker SR, Gandler HI, Ye DQ, Labella K, Mathur R, Toniolo PA, Tillgren M, Gokhale PC, Barbie D, Mullally A, Stegmaier K, Frank DA. +14 moreeuropepmc +1 more sourceGranulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer. [PDF]
Genes Cancer, 2015 Yeh JE, Kreimer S, Walker SR, Emori MM, Krystal H, Richardson A, Ivanov AR, Frank DA. +7 moreeuropepmc +1 more sourceDevelopment of Selective Covalent Janus Kinase 3 Inhibitors. [PDF]
J Med Chem, 2015 Tan L, Akahane K, McNally R, Reyskens KM, Ficarro SB, Liu S, Herter-Sprie GS, Koyama S, Pattison MJ, Labella K, Johannessen L, Akbay EA, Wong KK, Frank DA, Marto JA, Look TA, Arthur JS, Eck MJ, Gray NS. +18 moreeuropepmc +1 more sourceGene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.
Blood, 2016 Xiang M, Kim H, Ho VT, Walker SR, Bar-Natan M, Anahtar M, Liu S, Toniolo PA, Kroll Y, Jones N, Giaccone ZT, Heppler LN, Ye DQ, Marineau JJ, Shaw D, Bradner JE, Blonquist T, Neuberg D, Hetz C, Stone RM, Soiffer RJ, Frank DA. +21 moreeuropepmc +1 more source